GGrantIndex
← Search

IGF::OT::IGF NOVEL ANDROGEN RECEPTOR ANTAGONIST-MEDIATED CHEMOPREVENTION OF PROSTATE CANCER

$598,583N01FY2015CANIH

Iit Research Institute, Chicago IL

Investigators

Abstract

The overall objective of this task order is to evaluate ARN-509 in the inhibition of androgen-dependent prostate carcinogenesis induced in the Wistar-Unilever rat by N-methyl-N-nitrosourea (MNU) plus testosterone. Furthermore, this task order requires the contractor to optimize dosing regimen with an improved margin-of-safety, which would be able to translate into clinical studies for prostate cancer prevention. Furthermore, this task order also requires studying the chemopreventive efficacy of ARN-509 in association with AR-mediated cell proliferation, differentiation, and apoptosis in the prostate.

View original record on NIH RePORTER →